Akebia Therapeutics, Inc. (AKBA)
Automate Your Wheel Strategy on AKBA
With Tiblio's Option Bot, you can configure your own wheel strategy including AKBA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AKBA
- Rev/Share 0.7852
- Book/Share 0.1044
- PB 31.1366
- Debt/Equity 2.2028
- CurrentRatio 2.2338
- ROIC -0.0981
- MktCap 853567000.0
- FreeCF/Share -0.1479
- PFCF -24.5038
- PE -16.8907
- Debt/Assets 0.1746
- DivYield 0
- ROE 1.6665
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AKBA | Leerink Partners | -- | Outperform | -- | $7 | April 28, 2025 |
| Initiation | AKBA | Jefferies | -- | Buy | -- | $6 | April 1, 2025 |
News
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.
Read More
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Read More
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets.
Read More
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Read More
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Read More
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.
Read More
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Negative
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Read More
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up …
Read More
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Read More
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion.
Read More
About Akebia Therapeutics, Inc. (AKBA)
- IPO Date 2014-03-20
- Website https://www.akebia.com
- Industry Biotechnology
- CEO Mr. John P. Butler MBA
- Employees 181